



## ProKidney to Present at the 43rd Annual J.P. Morgan Healthcare Conference

January 7, 2025

WINSTON-SALEM, N.C., Jan. 07, 2025 (GLOBE NEWSWIRE) -- **ProKidney Corp. (Nasdaq: PROK)** ("ProKidney"), a late clinical-stage biotech company focused on the development of a first-in-class cell therapy candidate for chronic kidney disease (CKD), today announced that ProKidney's CEO, Bruce Culleton, M.D., will present at the 43<sup>rd</sup> Annual J.P. Morgan Healthcare Conference. The ProKidney management team will also host one-on-one meetings throughout the event.

### **43<sup>rd</sup> Annual J.P. Morgan Healthcare Conference**

**Date:** January 15, 2025

**Time:** 7:30am PST

**Format:** Presentation

**Webcast:** [Link](#)

The live webcast will also be accessible through the "Events" section of the Investor Relations tab within ProKidney's website at [www.prokidney.com](http://www.prokidney.com). Following the completion of the event, a replay will be available for 90 days.

### **About ProKidney Corp.**

ProKidney, a pioneer in the treatment of chronic kidney disease through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney's lead product candidate, rilparencel (also known as REACT<sup>®</sup>), is a first-in-class, patented, proprietary autologous cellular therapy being evaluated in Phase 2 and Phase 3 studies for its potential to preserve kidney function in diabetic patients at high risk of kidney failure. Rilparencel has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA. For more information, please visit [www.prokidney.com](http://www.prokidney.com).

### **Investor Contacts:**

ProKidney  
Ethan Holdaway  
[Ethan.Holdaway@prokidney.com](mailto:Ethan.Holdaway@prokidney.com)

LifeSci Advisors, LLC  
Daniel Ferry  
[Daniel@lifesciadvisors.com](mailto:Daniel@lifesciadvisors.com)